KLK3 and cancer: Another strategy is to replace the viral promoter with a tissue-specific one to limit viral replication to cells expressing specific antigens, e.g., hypoxia-induced factor 2 (HIF-2) or prostate-specific antigen (PSA), which are overexpressed in certain types of cancer cells [124,125].